Search Results for: 150

Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results

March 25, 2024 07:30 ET – The independent data monitoring committee (IDMC) recommended the continuation of VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma (PDAC), with no safety concerns raised – – VIRAGE remains on track to complete enrollment in the first half of 2024- – […]

Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results Read More »

Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros de todo el ejercicio 2023

March 25, 2024 07:30 ET – El Comité independiente para la monitorización de los datos (IDMC) ha recomendado la continuación de VIRAGE, ensayo clínico de fase 2b de VCN-01, en combinación con quimioterapia para el adenocarcinoma ductal pancreático (PDAC) metastásico, sin que se plantearan problemas de seguridad – – VIRAGE está en vías de finalizar la

Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros de todo el ejercicio 2023 Read More »

Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results

November 13, 2023 08:00 ET – VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma remains on track to complete enrollment in the first half of 2024; multiple patients have received second doses of VCN-01, which continues to be well tolerated with a safety profile consistent with

Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results Read More »

Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del tercer trimestre de 2023

November 13, 2023 08:00 ET – VIRAGE, el ensayo clínico de fase 2b de VCN-01 en combinación con quimioterapia para el adenocarcinoma ductal de páncreas metastásico, sigue el curso previsto para completar la inscripción en el primer semestre de 2024; muchos pacientes han recibido la segunda dosis de VCN-01, que sigue siendo bien tolerado y mantiene

Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del tercer trimestre de 2023 Read More »

Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del segundo trimestre de 2023

August 09, 2023 12:43 ET – Inicio de la dosificación en centros de EE. UU. de VIRAGE, el ensayo clínico de fase 2b de VCN-01 en combinación con quimioterapia en el adenocarcinoma ductal pancreático – – Las segundas dosis de VCN-01 intravenoso administradas a pacientes en España fueron bien toleradas y presentaron un perfil de

Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del segundo trimestre de 2023 Read More »

Theriva™ Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results

August 08, 2023 08:00 ET – Initiated dosing at U.S. sites for VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for Pancreatic Ductal Adenocarcinoma -Second doses of intravenous VCN-01 administered to patients in Spain and were well tolerated with a safety profile consistent with prior clinical trials – -VIRAGE remains on

Theriva™ Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results Read More »

Theriva Biologics presenta los aspectos operativos más destacados y los resultados financieros del primer trimestre de 2023

May 11, 2023 22:48 ET – Prosigue la inscripción de pacientes en VIRAGE, el ensayo clínico de fase 2b de VCN-01 administrado sistémicamente en combinación con quimioterapia en el adenocarcinoma ductal pancreático – – Presentación de datos del ensayo clínico de fase 1b/2a en curso de SYN-004 (ribaxamasa) en receptores de trasplantes alogénicos de células

Theriva Biologics presenta los aspectos operativos más destacados y los resultados financieros del primer trimestre de 2023 Read More »

Theriva™ Biologics Reports First Quarter 2023 Operational Highlights and Financial Results

May 11, 2023 08:00 ET – Continued to enroll patients in VIRAGE, the Phase 2b clinical trial of systemically administered VCN-01 in combination with chemotherapy for Pancreatic Ductal Adenocarcinoma – – Presented data from the ongoing Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant recipients at the 33rd European Congress of

Theriva™ Biologics Reports First Quarter 2023 Operational Highlights and Financial Results Read More »

Theriva Biologics Announces Presentation of Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

– Interim blinded safety and pharmacokinetic data to be presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) – April 13, 2023 08:00 ET ROCKVILLE, Md., April 13, 2023 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer

Theriva Biologics Announces Presentation of Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients Read More »

Theriva™ Biologics Announces Presentation of Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

– Interim blinded safety and pharmacokinetic data to be presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) – April 13, 2023 08:00 ET ROCKVILLE, Md., April 13, 2023 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer

Theriva™ Biologics Announces Presentation of Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients Read More »